The Patent Finder

Terms ending in 2044

Genmab A/S

Every in-force patent on Genmab A/S's record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,410,258Antibodies Capable of Binding to OX40, Variants Thereof and Uses Thereof
In force
 · High confidence
BioNTech SEIn forceHigh confidence
US 12,351,650Antibodies Binding to Fibroblast Activation Protein Alpha and Death Receptor 4
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,780,930Antibodies Capable of Binding to CD27, Variants Thereof and Uses Thereof
In force
 · High confidence
Genmab A/SIn forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Genmab A/S.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited